LUMOXITI

Peak

moxetumomab pasudotox-tdfk

BLAINJECTIONINJECTABLEPriority Review
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1

Clinical Trials (1)

NCT04125290N/ATerminated

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

Started Dec 2019
2 enrolled
Hairy Cell Leukemia